PD-L1 Expression on Immune and Tumor Cells
US Pathologist, Dr. Michael Lynch, from the Medical and Scientific Affairs (MSA) department for Roche Tissue Diagnostics discusses:
1. How and why PD-L1 is present on tumor cells as well as being
present on immune cells
2. The different tumor types that show PD-L1 expression
3. The dramatic response of some patients to anti-PD- L1 or anti-PD- 1 therapy, or immunotherapy
4. The diagnostic tests that are available for PD-L1 and how they should be used
5. The SP142 diagnostic assay and how it stains both tumor cells and immune cells
6. The patterns of staining and why they might be important
For questions, comments, or study ideas please contact your U.S. medical and scientific affairs manager or email them at: RIDFCT_PATHEDU@msxdl.roch.com
PP-US-13146 (Video)
PP-US-13147 (script and references)
Видео PD-L1 Expression on Immune and Tumor Cells канала RocheDiagnosticsUSA
1. How and why PD-L1 is present on tumor cells as well as being
present on immune cells
2. The different tumor types that show PD-L1 expression
3. The dramatic response of some patients to anti-PD- L1 or anti-PD- 1 therapy, or immunotherapy
4. The diagnostic tests that are available for PD-L1 and how they should be used
5. The SP142 diagnostic assay and how it stains both tumor cells and immune cells
6. The patterns of staining and why they might be important
For questions, comments, or study ideas please contact your U.S. medical and scientific affairs manager or email them at: RIDFCT_PATHEDU@msxdl.roch.com
PP-US-13146 (Video)
PP-US-13147 (script and references)
Видео PD-L1 Expression on Immune and Tumor Cells канала RocheDiagnosticsUSA
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
Tumor Microenvironment and PD-L1 biomarkerHow is Immunotherapy Used to Fight Cancer? | Dana-Farber Cancer Institute | Science IllustratedCTLA4 and attenuation of T cell responsePD-L1 Testing and Developmental Process for Companion Diagnostic TestsTargeting the immune system with checkpoint inhibitorsStanford Cancer Institute - CD47 DiscoveryPD-L1 Testing in Non-Small Cell Lung CarcinomaAdvanced NSCLC: Refining Clinical Pathways in the Rapidly Evolving Therapeutic LandscapeGI chemotherapy education - FolfoxBeyond Checkpoint Blockade for Cancer ImmunotherapyHow Keytruda Cancer Treatment Works (Update)Webinar - PD-1/PD-L1 Inhibitors: The First Wave of Immuno-OncologyHow to intepret a PD-L1 immunostainHistory of Immunotherapy by James Allison at PMWC 2017 Silicon ValleyCancer immunotherapy | The PD-L1 pathwayAll you need to know about PD-L1 by ImmunohistochemistryThe science of cells that never get old | Elizabeth BlackburnDan Littman (NYU / HHMI) 2: Shaping of Immune Responses by the MicrobiotaUnderstanding the Cells of the Immune SystemPharmacology - CANCER DRUGS - HORMONAL THERAPY (MADE EASY)